Prof. Carl Heneghan Director CEBM University of Oxford

Slides:



Advertisements
Similar presentations
The MADIT II Trial Multicenter Autonomic Defibrillator Implantation Trial II Presented at the American College of Cardiology 51st Annual Scientific Session.
Advertisements

Ten years of the CHD NSF Professor Roger Boyle CBE National Director for Heart Disease and Stroke Department of Health.
Progress Against Head and Neck Cancer. 1970–1979.
Lessons from STEP-BD for the Treatment of Bipolar Disorder
Implementing NICE guidance
Allison Dunning, M.S. Research Biostatistician
17 th Workshop on Teaching Evidence- Based Practice St Hugh’s College 2010 Dr Carl Heneghan MA, MRCGP, DPhil Director CEBM University of Oxford.
Multicenter Automatic Defibrillator Implantation Trial II
UPDATE ON THROMBOLYTIC THERAPY Markku Kaste Department of Neurology Helsinki University Central Hospital (HUCH) University of Helsinki Markku Kaste Department.
Evidence Based Health Care Course Paris, 2010 Appraising diagnostic studies Dr Matthew Thompson Senior Clinical Scientist.
Breaking news from IST-3 Peter Sandercock University of Edinburgh on behalf of the IST-3 collaborative group ESC London 29 th May 2013.
© CM Gibson 2006 Cross-sections of left ventricle after experimental coronary artery occlusion Cross-sections of left ventricle after experimental coronary.
Evidence-Based Medicine Thread Course Dr Carl Heneghan Director CEBM Clinical Reader, University of Oxford.
1-day workshop on Evidence-Based Practice November 26 th 2010 Dr Carl Heneghan Clinical Reader, University of Oxford Director CEBM.
3-Day workshop on Evidence-Based Practice March 26 th 2012 Dr Carl Heneghan Director CEBM Clinical Reader, University of Oxford.
Looking for lower value and overuse Professor Carl Heneghan Director CEBM University of Oxford.
Evidence-Based Practice April 8 th 2013 Dr Carl Heneghan Clinical Reader, University of Oxford Director CEBM.
Stroke Care. What has been achieved so far and what still needs doing? Tony Rudd.
CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.
Purpose To determine whether metoprolol controlled/extended release
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2014.
Evidence-based Medicine Journal Club Khalid Bin Abdulrahman Director of Medical Education Center King Saud University.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2010.
Ablation for Paroxysmal Atrial Fibrillation (APAF) Trial Presented at The American College of Cardiology Scientific Session 2006 Presented by Dr. Carlo.
A stroke is the leading cause of permanent impairment and disability. Pending a radical cure, patients recovering from a stroke will continue to require.
John M. Diamond, MD Professor and Head, Division of Child and Adolescent Psychiatry Brody School of Medicine at East Carolina University.
The level of evidence utilized to answer general practitioners’ questions Karen Davies.
EVIDENCE BASED MEDICINE Effectiveness of therapy Ross Lawrenson.
Chapter 1. Chapter 2 Dr Spock 1956 edition switches his recommendation to face down USA Second study Suggests harm First.
21 st Workshop on Teaching Evidence-Based Practice 2015 Carl Heneghan MA, MRCGP, DPhil Professor of EBM & Director CEBM University of Oxford.
Evidence based stroke medicine. Evaluating treatments for acute ischaemic stroke -what works and what doesn’t? Professor Peter Sandercock.
Prevention of Recurrent Venous Thromboembolism N Engl J Med Apr ;348(15) : PREVENT (Warfarin) Trial.
Ardiana Murtezani MD, PhD 1, 2, Nerimane Abazi MD 1,2, Zana Ibraimi PHARM PhD 2,Fatime Haxholli MD 1,2, Zana Agani DDS PhD 2,3, Elena Kamberi DDS 2.
CAST: Cardiac Arrhythmia Suppression Trial Purpose To determine whether therapy with class Ic antiarrhythmics to suppress asymptomatic or mildly symptomatic.
Evidence based stroke medicine. Evaluating treatments for acute ischaemic stroke -what works and what doesn’t? Professor Peter Sandercock.
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
Cardiovascular Drugs That Prolong The QT Interval
When is a meta-analysis helpful? EBM: 9/18/2012. Evidence-based medicine 25 year old woman presents with an acute migraine. She doesn’t respond to subcutaneous.
EXAMINATION Objective Assess the safety and performance of a new-generation DES vs. a BMS in the setting of primary PCI for treatment of patients with.
Survival of Patients with Acute Heart Failure in Need of Intravenous Inotropic Support SURVIVE-WSURVIVE-W Presented at The American Heart Association Scientific.
And other Lies and Damned Lies
No improvement in 30-day mortality with high-dose Glucose-Insulin-Potassium (GIK) infusion CREATE-ECLA - GIK Trial Presented at: American Heart Association.
This material was developed by Oregon Health & Science University, funded by the Department of Health and Human Services, Office of the National Coordinator.
EP show – June 2004 EP show The EP show: Risk stratification for sudden death Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent.
Research Design Evidence Based Medicine Concepts and Glossary.
EBM --- Journal Reading Presenter :林禹君 Date : 2005/10/26.
Dr Michelle Webb Renal Consultant, Associate Medical Director Patient Safety, East Kent Hospitals University NHS Foundation Trust and Co-lead for Sepsis.
Date of download: 5/31/2016 Copyright © The American College of Cardiology. All rights reserved. From: Mechanical Thrombectomy for Acute Ischemic Stroke:
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer Anna Bill-Axelson, M.D., Lars Holmberg, M.D., Ph.D., Mirja Ruutu, M.D., Ph.D., Michael.
Critical Appraisal Course for Emergency Medicine Trainees Module 3 Evaluation of a therapy.
Critical Appraisal of a Paper Feedback. Critical Appraisal Full Reference –Authors (Surname & Abbreviations) –Year of publication –Full Title –Journal.
Impact of Low-molecular-weight Heparin (Reviparin) on Mortality, Reinfarction, and Stroke in Patients with Acute MI CREATE-ECLA - Reviparin Presented at:
EBM R1張舜凱.
The American College of Cardiology Presented by Dr. Adnan Kastrati
A stroke is the leading cause of permanent impairment and disability
Arch Intern Med. 2007;167(1): doi: /archinte Figure Legend:
Thrombectomy in Acute Stroke
Martha Carvour, MD, PhD March 2, 2017
1. Evidence based management:
Figure 1. Nonadherence to guidelines for prescribing antiplatelet and anticoagulant therapy in 144 patients with atrial fibrillation who attend a Spanish.
DAPT Trial design: Patients undergoing DES/BMS PCI, no ischemic/bleeding complications, and with documented compliance at 1 year, were randomized to receive.
Neil J. Stone et al. JACC 2014;63:
Catheter Ablation for the Cure of Atrial Fibrillation Study
Modified Rankin score 0-2
AMISTAD II: Study Design
NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.
Module 4 Finding the Evidence: Individual Trials
Live on PAH: Breathing Life Into Patients With PAH
Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care  Marc Cohen, MD  Mayo Clinic Proceedings 
Three outcome measures from the NINDS tPA trial
Presentation transcript:

Prof. Carl Heneghan Director CEBM University of Oxford www.cebm.net Evidence-Based Medicine Prof. Carl Heneghan Director CEBM University of Oxford

www.cebm.net

What is Evidence-Based Medicine? “Evidence-based medicine is the integration of best research evidence with clinical expertise and patient values” Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS: Evidence based medicine: what it is and what it isn’t. BMJ 1996;312:71-2. This definition of what EBM is and isn’t has gained wide acceptance and made it easier for us to get our points across.

5

Why do we need EBM?

The CAST trial revealed Excess mortality of 56/1000. Why do we need RANDOMIZED CONTROLLED TRIALS ? www.cebm.net In the early 1980s newly introduced antiarrhythmics were found to be highly successful at suppressing arrhythmias. Not until a RCT was performed was it realized that, although these drugs suppressed arrhythmias, they actually increased mortality. The CAST trial revealed Excess mortality of 56/1000. By the time the results of this trial were published, at least 100,000 such patients had been taking these drugs.

• For every 1000 patients treated 65 more will be alive at 1 month if treatment is administered in the first hour – the ‘golden hour’ – after symptom onset, compared with not giving thrombolysis; • 37 lives are saved for every 1000 patients treated in the 1–2 hour interval after symptom onset; • 26 lives are saved for every 1000 patients treated in the 2–3 hour interval after symptom onset; • 29 lives are saved for every 1000 patients treated in the 3–6 hour interval after symptom onset; • 20 lives are saved for every 1000 patients treated in the 7–12 hour interval after symptom onset.

Allocation to antiplatelet therapy produced a highly significant reduction (P<0.00001) of 38 per 1000 in the risk of suffering a subsequent vascular event

Pain relief

Beware of text books

“A 21st century clinician who cannot critically read a study is as unprepared as one who cannot take a blood pressure or examine the cardiovascular system.” BMJ 2008:337:704-705

EBM as a medical student?

Be aware that treatment options should be based on clinical need and the effectiveness of treatment options, and that decisions should be arrived at through assessment and discussion with the patient

Must be aware of their responsibility to maintain their knowledge and skills throughout there careers. Students are expected to keep up to date and to apply knowledge necessary for good clinical care.

what skills will you need to keep up to date with the best evidence? Must be aware of their responsibility to maintain their knowledge and skills throughout there careers. Students are expected to keep up to date and to apply knowledge necessary for good clinical care. what skills will you need to keep up to date with the best evidence? to find the evidence more efficiently to appraise the quality of the evidence more effectively to use good quality evidence more systematically

about 1/2 of ‘valid’ evidence today is out of date in 5 years about 1/2 of valid evidence is not implemented ScienceCartoonsPlus.com

the steps of practicing EBM 1. Ask a focused question. 2. Track down the evidence 3. Critically appraise evidence for its validity, effect size, precision 4. Apply the evidence in practice: amalgamate the valid evidence with other relevant information (values & preferences, clinical/health issues, & system issues) implement the decision in practice We will introduce you to these 4 steps of EBP and many of the processes you can use to help make more evidence-based decisions

1. Ask a focused question. Patient presenting with MI

‘Background’ Questions About the disorder, test, treatment, etc. a. Root* + Verb: “What causes …” b. Condition: “HIV?” * Who, What, Where, When, Why,

Patient presenting with MI What are the symptoms and signs of someone presenting with MI? 2. What are the diagnostic tests for MI? 3. What are the causes of MI? 4. What are the treatments of MI?

Know your background

Compared to placebo Patient presenting with MI Foreground’ Questions About actual patient care decisions and actions For treatment 4 (or 3) components: In Patients with a MI Does (I) cholesterol lowering therapy Compared to placebo reduce mortality (O)

During the scheduled treatment period, there were 3832 (8·5%) deaths among the 45 054 participants allocated a statin compared with 4354 (9·7%) among the 45 002 controls. This difference represents a 12% proportional reduction in all-cause mortality per mmol/L LDL cholesterol reduction (RR 0·88, 95% CI 0·84–0·91; p<0·0001; figure 1).

Secondary Prevention Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study 9,014 patients with a history of MI or hospitalization for unstable angina randomized to pravastatin (40 mg) or placebo for 6.1 years Statins provide significant benefit across a broad range of cholesterol levels 24% RRR 9 8.3 6.4 CHD Death (%) 6 The LIPID study sought to evaluate the effect of statins in secondary prevention among those with a broad range of cholesterol levels. Patients with a history of known coronary artery disease were randomized to pravastatin (40 mg) or placebo over a mean of 6.1 years. Patients receiving pravastatin experienced a significant 24% relative risk reduction in coronary heart disease mortality, with no clinically significant adverse effects. 3 P<0.001 Placebo Pravastatin CHD=Coronary heart disease, MI=Myocardial infarction, RRR=Relative risk reduction LIPID Study Group. NEJM 1998;339:1349–1357

Patient presenting with MI 1. How common is the problem Prevalence 2. Is early detection worthwhile Screening 3. Is the diagnostic test accurate Diagnosis 4. What will happen if we do nothing Prognosis 5. Does this intervention help Treatment 6. What are the common harms of an intervention 7. What are the rare harms of an intervention

Size of Medical Knowledge NLM MetaThesaurus 875,255 concepts 2.14 million concept names Diagnosis Pro 11,000 diseases 30,000 abnormalities (symptoms, signs, lab, X-ray,) 3,200 drugs (cf FDAs 18,283 products) 1 disease per day for 30 years To cover the vast field of medicine in four years is an impossible task. - William Olser

why do we need to use evidence efficiently? PRESENTATION ONE 6/04/2017 why do we need to use evidence efficiently? 5,000? per day 2,000 per day 75 per day Articles Per Year so why do we need to use the evidence more efficiently today? Because there is an epidemic of evidence we need to keep up with and we cannot do this without new skills EBP: informing decisions with the best up-to-date evidence Introduction to Evidence-Based Practice

Median minutes/week spent reading about my patients Self-reports at 17 Grand Rounds: Medical Students: 90 minutes House Officers (PGY1): 0 (up to 70%=none) SHOs (PGY2-4): 20 (up to 15%=none) Registrars: 45 (up to 40%=none) Sr. Registrars 30 (up to 15%=none) Consultants: Grad. Post 1975: 45 (up to 30%=none) Grad. Pre 1975: 30 (up to 40%=none) This summarises the data from about 12 DGH’s around the England and Scotland. In summary, HO’s (who don’t read at all) are being taught by old farts (who read 30 minutes a week). 36

clinical evidence increasing so rapidly we need better skills to keep up-to-date more efficiently than previous generations of clinicians the figure on this slide illustrates the modern epidemic of evidence. The solid blue line shows the growth in number of published randomised controlled trials and you can see the dramatic increase in trials - with more than 5 times as many published today than in the 1980s. So its not surprising that we need to be far more efficient in keepoing up to date with the evidence today than we did 20-30 years ago. and Given that many of today's health professionals did most of their training more than 30 years ago, there is a lot of upskilling needed. as an aside ...I was running an EBP workshop in Iran a few years ago and I had made a statement that one couldn't be a quality practitioner without EBP skills. An elderly physician near the front of the room put up his hand and said that this was his first EBP workshop so did that mean that for most of his practicing life he had been a poor quality doctor. My response was that for most of his practicing life, he could probably have kept up with the evidence without any specific EBP skills because there wasn't a lot of good clinical epidemiological evidence around but that was now changing rapidly and so he now needed these skills.   more efficiently Bastian, Glasziou, Chalmers PLoS 2010 Vol 7 | Issue 9 | e1000326 37

the steps of practicing EBM 1. ask a focused question. 2. Track down the evidence 3. Critically appraise evidence for its validity, effect size, precision 4. apply the evidence in practice: a. amalgamate the valid evidence with other relevant information (values & preferences, clinical/health issues, & system issues) and make an evidence-based decision; and b. implement the decision in practice We will introduce you to these 4 steps of EBP and many of the processes you can use to help make more evidence-based decisions

the steps of practicing EBM 1. Ask a focused question. 2. Track down the evidence 3. Critically appraise evidence for its validity, effect size, precision (NEXT month) 4. Apply the evidence in practice: amalgamate the valid evidence with other relevant information (values & preferences, clinical/health issues, & system issues) implement the decision in practice We will introduce you to these 4 steps of EBP and many of the processes you can use to help make more evidence-based decisions

In the next 4 weeks Try to ask for one patient you have seen: What causes the disease? How was the disease diagnosed? How was the patient treated? What is the natural history of the disease? Consider formulating a PICO And try to find some evidence